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Pseudocholinesterase Deficiency: Implications in Anesthesia
Amanda Esselstein, RN, BSN, SRNA
Introduction
The use of neuromuscular blocking 
medications is a frequent and essential 
practice in establishing a secure airway 
in patients preparing for surgery or in 
emergent situations such as respiratory 
distress.  As an anesthesia provider, it is 
vital to know the mechanism of action, 
expected duration, and metabolism of 
these neuromuscular blocking agents 
particularly succinylcholine.  A potential 
serious complication that may occur in 
patients that have been administered 
succinylcholine is prolonged 
neuromuscular blockade due to the 
deficiency of pseudocholinesterase, the 
enzyme produced in the liver and 
present in plasma that metabolizes 
succinylcholine (Branch, Rafacz, & 
Boudreaux, 2011).  In patients with a 
pseudocholinesterase deficiency, 
succinylcholine is not broken down as 
quickly as would be expected, which 
produces a prolonged neuromuscular 
block. These patients will need 
continuous ventilator support post-
operatively and often admission to the 
intensive care unit until muscle strength 
is restored (Stoelting & Hiller, 2015).
Identifying those patients at risk and 
recognizing the signs of 
pseudocholinesterase deficiency are key 
in avoiding complications associated 
with an abnormally prolonged 
neuromuscular block.  
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• Pseudocholinesterase is an enzyme 
produced in the liver that 
metabolizes neuromuscular 
blocking agents, particularly 
succinylcholine and mivarcurium, 
as well as some local anesthetics.  
• Pseudocholinesterase hydrolyzes 
succinylcholine in the plasma so 
quickly that only 10% of the 
medications actually reaches and 
acts upon the neuromuscular 
junction (NMJ). 
• Once at the NMJ, succinylcholine 
binds to acetylcholine receptor 
sites causing sustained 
depolarization for a relatively short 
period of time in which the patient 
experiences skeletal muscle 
fasiculations followed by flaccid 
paralysis. 
• Succinylcholine diffuses away from 
the NMJ down its concentration 
gradient at which point muscle 
function will return.  
• Typically, an intubating dose of 
succinylcholine is rapidly 
hydrolyzed by 
pseudocholinesterase within 9 to 
13 minutes in which 90% of the 
muscle strength will be restored, 
however its duration of action will 
be prolonged in a deficient patient 
depending on the type of genetic 
abnormality present.
.
• Pseudocholinesterase deficiency is 
caused by either a homozygous or 
heterozygous abnormal genetic 
variant of the enzyme itself.  An 
individual that is homozygous for the 
atypical gene which occurs in one in 
every 3,500 people, the 
neuromuscular block produced by 
succinylcholine will likely last four to 
eight hours and this genotype is more 
likely to experience apnea and the 
inability to be taken off of the 
ventilator post-operatively.  
• An individual with a heterozygous 
gene which occurs one in every 480 
people, will experience the effects of 
succinylcholine two times longer than 
an individual with a normal genotype. 
• There are multiple other causes that 
are less significant, but may cause a 
decrease in pseudocholinesterase 
activity including liver disease, old 
age, pregnancy, burns, malnutrition, 
neoplastic disease, the use specific 
mediations such as reglan, oral 
contraceptives, monamine oxidase 
inhibitors, and anticholinesterase 
medications (Stoelting & Hiller, 
2015).
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• A patient with pseudocholinesterase deficiency will not experience signs or 
symptoms unless he or she is administered a neuromuscular blocking agent.
• The major presenting sign is prolonged skeletal muscle paralysis including the 
diaphragm and intercostal muscles that are required for the patient to breath.
• Apnea and a lack of movement or muscle twitches when using a peripheral nerve 
stimulator will present until the medication is metabolized by the body which may 
not be until hours later (Whittington, et. al, 2012).
• The peripheral nerve stimulator is a method for monitoring neuromuscular 
blockade in which electrodes are placed either on the facial or ulnar nerve and 
stimulated using various modes to produce a muscle twitch.  Train-of-four is a 
commonly used mode in which four simultaneous stimuli are delivered and the 
number and strength of the tissues is observed by the anesthesia provider.  The 
goal after using a neuromuscular blocking agent and prior to extubation is four 
twitches without fade which refers to the strength of the twitch.  An individual 
with a pseudocholinesterase deficiency may not produce any twitches depending 
the amount of time that has passed since administration and the type of genetic 
variant (Nagelhout, & Plaus, 2013).
Pathophysiology Significance of Pathophysiology
• While pseudocholinesterase deficiency is not one of the most common 
complications seen with general anesthesia, it can be fatal if not recognized and 
treated properly. 
• Since we know there is a genetic link, a thorough pre-operative assessment should 
be completed including family history of this condition.  Sometimes asking if the 
patient or a family member was admitted to the ICU or had to be on the ventilator 
for longer than expected after surgery will help to reveal a pseudocholinesterase 
deficiency.  
• The deficiency is most often found after succinylcholine has already been given 
and it is discovered that the patient’s muscle function has not returned within the 
expected time frame.
• There is no treatment for this genetic condition, however supportive care, 
particularly ventilator support, must be given until the medication has been 
adequately metabolized and the patient has regained muscle strength (Stoelting & 
Hiller, 2015).
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Implications for Nursing Care
• Nursing anesthesia providers to know the mechanism of action and potential 
adverse effects of all medications especially neuromuscular blockers in order 
properly recognize and treat a pseudocholinesterase deficiency. 
• Always assess muscle function using train of four monitoring with a peripheral 
nerve stimulator prior to an after a neuromuscular blockade is given.  This will 
allow for comparison and the provider can be more confident in the degree of 
muscle strength recovery prior to making the decision to extubate the patient 
(International Anesthesia Research Society, 2016).
• Do not extubate a patient that has not experienced muscle recovery, provide full 
ventilator support, and make arrangements for a ventilator set-up in the PACU 
or ICU.
• Avoid the use of succinylcholine unless absolutely necessary and do not give 
unless the benefits outweigh the potential costs (Quyen, 2012).
• PACU and ICU nurses should familiarize themselves with the significance of a 
pseucholinesterase deficiency, the use of a peripheral nerve stimulator, and the 
necessary care for these patients postoperatively.  
Conclusion
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• This condition will not affect the patient’s everyday life, however it may become 
a life-threatening condition if the patient must undergo general anesthesia for 
surgery.  
• For this reason anesthesia providers should always consider using less invasive 
airway options or nerve blocks, both of which would not require the 
administration of neuromuscular blocking agents, like succinylcholine. 
• If the use of a NMB cannot be avoided and there are no absolute 
contradindications, then providers must be prepared to recognize, assess and 
provide support to a patient that presents with a pseucholinesterase deficiency.  
